10 Best Healthcare Stocks to Buy According to Wall Street Analysts
The article says the U.S. healthcare sector lagged the market for three straight years, returning 0.3% (2023), 0.9% (2024) and 12.5% (2025), and is down 1.62% YTD in 2026 vs. the S&P 500’s 10.35% gain. Analysts cite AI-focused capital shifts and valuation gaps. It lists 10 healthcare stocks screened for ≥20% upside; examples include Elanco (ELAN) with a TD Cowen price target raised to $32 and Agilent (A) with a Piper Sandler $150 target plus an OpenAI/BCG AI collaboration.
How this was made
The 30-second read
Why it matters
For traders, the actionable items are the specific company catalysts cited (ELAN’s venture fund; A’s AI collaboration and PT initiation). However, the article is largely a curated list with limited quantified financial impact, reducing immediacy.
Market read
Company-specific announcements and analyst PT changes provide some catalyst-level information, but the overall format is promotional and lacks new, decision-grade financial guidance.
What to watch
The article omits valuation context, consensus estimates, and whether the cited PT changes reflect new fundamentals versus model assumptions; also no risk discussion (execution, competitive dynamics, China exposure for A).
Background
The piece argues healthcare has lagged the broader market and frames the opportunity as valuation plus selective catalysts.
Ticker impact
Elanco (ELAN) announced Elanco Ventures with a $25M multi-year commitment, plus TD Cowen raised its price target to $32 from $31.
Mild positive bias; likely supports upside skew but not a fundamental re-rate on its own.
The article cites a specific new program (Elanco Ventures) and a concrete PT change, but provides no immediate financial guidance or deal size beyond the $25M fund commitment.
Agilent (A) began coverage with a $150 Neutral PT from Piper Sandler and also announced an AI collaboration with OpenAI and BCG.
Mixed-to-neutral near term: PT initiation offsets enthusiasm from the AI partnership.
The text includes two discrete catalysts (AI collaboration and PT initiation), but lacks quantified revenue/earnings impact or timing beyond partnership intent.
Market effects
Reinforces the narrative that healthcare is a valuation opportunity versus AI-led markets, but provides no new sector-wide data.
Primarily US healthcare equities; no direct cross-region linkage beyond general market commentary.
Limited—only company-specific initiatives and analyst notes, not global regulatory or macro shocks.
Counterpoint
A “best stocks” list may overweight analyst optimism and strategic announcements that don’t yet translate into measurable near-term earnings.
Key entities
- companyElanco Animal Health Incorporated
Announced Elanco Ventures ($25M multi-year commitment) and received a TD Cowen price-target increase.
- companyAgilent Technologies, Inc.
Announced AI collaboration with OpenAI and BCG; received Piper Sandler Neutral initiation with a $150 PT.
- market participantsWall Street analysts (as a group)
Used as the basis for the “best healthcare stocks” ranking methodology.
